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Ezetimibe alone or in combination with simvastatin increases
small dense low-density lipoproteins in healthy men: a
randomized trial
Abstract
AIMS: The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with
increased cardiovascular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully
elucidated. This study assessed by gradient gel electrophoresis the effects of ezetimibe alone,
simvastatin alone, and their combination on sdLDL subfraction distribution.
METHODS AND RESULTS: A single-centre, randomized, parallel three-group open-label study was
performed in 72 healthy men with a baseline LDL-cholesterol (LDL-C) concentration of 111 +/- 30
mg/dL (2.9 +/- 0.8 mmol/L). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40
mg/day, n = 24), or their combination (n = 24) for 14 days. Blood was drawn before and after the
treatment period. Generalized estimating equations were used to assess the influence of drug therapy on
LDL subfraction distribution, controlling for within-subject patterns (clustering). We adjusted for age,
body mass index, and baseline concentrations of LDL-C and triglycerides. Ezetimibe alone changed
LDL subfraction distribution towards a more atherogenic profile by significantly increasing sdLDL
subfractions (LDL-IVA +14.2%, P = 0.0216 and LDL-IVB +16.7%, P = 0.039; fully adjusted Wald
chi(2) test). In contrast, simvastatin alone significantly decreased the LDL-IVB subfraction (-16.7%, P =
0.002). This effect was offset when simvastatin was combined with ezetimibe (LDL-IVB +14.3%, P =
0.44). All three treatments decreased the large, more buoyant LDL-I subfraction, the effects of ezetimibe
being the most pronounced (ezetimibe -13.9%, P < 0.0001; combination therapy -7.3%, P = 0.0743;
simvastatin -4.6%, P < 0.0001).
CONCLUSION: In healthy men, treatment with ezetimibe alone is associated with the development of a
pro-atherogenic LDL subfraction profile. Potentially atheroprotective effects of simvastatin are offset by
ezetimibe. This study is registered with ClinicalTrials.gov, identifier no. NCT00317993.
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Aims The predominance of small dense low-density lipoproteins (sdLDLs) has been associated with increased cardiovas-
cular risk. The effect of ezetimibe on LDL subfraction distribution has not been fully elucidated. This study assessed
by gradient gel electrophoresis the effects of ezetimibe alone, simvastatin alone, and their combination on sdLDL
subfraction distribution.
Methods
and results
A single-centre, randomized, parallel three-group open-label study was performed in 72 healthy men with a baseline
LDL-cholesterol (LDL-C) concentration of 111+ 30 mg/dL (2.9+ 0.8 mmol/L). They were treated with ezetimibe
(10 mg/day, n ¼ 24), simvastatin (40 mg/day, n ¼ 24), or their combination (n ¼ 24) for 14 days. Blood was drawn
before and after the treatment period. Generalized estimating equations were used to assess the influence of
drug therapy on LDL subfraction distribution, controlling for within-subject patterns (clustering). We adjusted for
age, body mass index, and baseline concentrations of LDL-C and triglycerides. Ezetimibe alone changed LDL subfrac-
tion distribution towards a more atherogenic profile by significantly increasing sdLDL subfractions (LDL-IVA +14.2%,
P ¼ 0.0216 and LDL-IVB +16.7%, P ¼ 0.039; fully adjusted Wald x2 test). In contrast, simvastatin alone significantly
decreased the LDL-IVB subfraction (216.7%, P ¼ 0.002). This effect was offset when simvastatin was combined with
ezetimibe (LDL-IVB +14.3%, P ¼ 0.44). All three treatments decreased the large, more buoyant LDL-I subfraction,
the effects of ezetimibe being the most pronounced (ezetimibe –13.9%, P, 0.0001; combination therapy 27.3%,
P ¼ 0.0743; simvastatin 24.6%, P, 0.0001).
Conclusion In healthy men, treatment with ezetimibe alone is associated with the development of a pro-atherogenic LDL sub-
fraction profile. Potentially atheroprotective effects of simvastatin are offset by ezetimibe.
This study is registered with ClinicalTrials.gov, identifier no. NCT00317993.
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Introduction
Ezetimibe represents the first of a new class of lipid-lowering
agents, the cholesterol absorption inhibitors. It is able to reduce
low-density lipoprotein cholesterol (LDL-C) by 15–25% when
given as monotherapy or added on an ongoing statin treatment.1,2
Owing to the complementary mechanism of action of ezetimibe
and statins (inhibition of cholesterol absorption and synthesis,
respectively) and to their additive effects on LDL-C lowering,
their combination is widely used to achieve reductions in LDL-C
of up to 60%.3,4
However, a substantial body of evidence suggests that the
‘quality’, and not only the ‘quantity’, of LDL exerts a direct influence
on cardiovascular risk (reviewed in Superko and Gadesam5 and
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Rizzo and Berneis6). Low-density lipoprotein consists of a set of dis-
crete subfractions with distinct molecular properties, among them
size and density. In normal subjects, seven major LDL subfractions
can be identified [I (large), IIA and IIB (medium), IIIA and IIIB
(small), and IVA and IVB (very small)]. Low-density lipoprotein-I is
the largest and least dense and LDL-IVB is the smallest, most
dense particle.7 The predominance of small dense LDL (sdLDL)
and of small LDL particle size (diameter ,258 A˚) has been associ-
ated with increased cardiovascular risk.5,8–11 In this context, the
LDL-IVB subfraction has been found to be the single best lipopro-
tein predictor for atherosclerotic disease progression.12
Statins have been shown to have either no or only a moderate
effect on LDL subclass distribution or particle size.13 Few studies
have so far assessed the effects of ezetimibe on LDL particle size
and/or subfraction distribution (as reviewed in Rizzo et al.14), with
conflicting results. Furthermore, most of these trials included subjects
with concomitant metabolic disorders such as obesity, hypercholes-
terolaemia, diabetes, and the metabolic syndrome, and with a
variety of co-medications with unknown effects on lipoproteins.
The recent ENHANCE trial found that although the addition of
ezetimibe (10 mg/day) to simvastatin (80 mg/day) in patients with
heterozygous familial hypercholesterolaemia caused an additional
16.5% reduction in LDL-C, it did not significantly affect the
primary endpoint, i.e. the mean change in intima–media thickness
(IMT), compared with simvastatin monotherapy.15 Subsequently,
the value of ezetimibe in the arena of cardiovascular prevention
was questioned, and although various theories have been pro-
posed to explain these surprising results, the actual reasons
remain unclear.16,17
The purpose of the present study was to test the hypothesis
that ezetimibe may alter LDL subfraction distribution and particle
size towards a pro-atherogenic profile in healthy subjects.
Methods
Study design
Low-density lipoprotein particle size and subfractions were analysed
from frozen samples of a single-centre, randomized, parallel
three-group open-label study that investigated the effects of ezetimibe
and simvastatin, alone or in combination, on lipid metabolism. The
primary results of this randomized trial have been reported pre-
viously.4,18 A total of 72 subjects were randomized to receive ezeti-
mibe (10 mg/day), simvastatin (40 mg/day), or ezetimibe (10 mg/day)
plus simvastatin (40 mg/day) for 2 weeks (n ¼ 24 for each group). Eze-
timibe and simvastatin were taken once a day in the evening. Blood was
drawn before the initiation of treatment and at the end of the treat-
ment period, and the samples were analysed in a blinded manner.
Subjects
Inclusion criteria were age between 18 and 60 years, body mass index
(BMI) between 18.5 and 30 kg/m2, fasting LDL-C concentrations
,190 mg/dL, triglyceride concentrations ,250 mg/dL, and normal
blood pressure (,140/90 mmHg). Subjects who had received
lipid-lowering drugs within 12 weeks prior to study entry, those with
a history of excessive alcohol intake, liver disease, renal dysfunction
(glomerular filtration rate ,60 mL/min), coronary heart disease, dia-
betes mellitus or other endocrine disorders, eating disorders, a
history of recent substantial (.10%) weight change, a history of
obesity (BMI . 35 kg/m2), or taking medications known to affect lipo-
protein metabolism were excluded from the study.
The protocol was approved by the Ethics Committee of the Univer-
sity of Cologne, and all subjects gave written informed consent. The
study conformed to the Declaration of Helsinki. All subjects com-
pleted the study. Body weight did not change in any treatment
group. The subjects did not use any extra medications, had no illnesses,
and did not deviate from the study protocol. No serious side effects
were reported.
Biochemical analyses
Blood was drawn by venipuncture in the morning after a 12 h fast to
obtain serum for analysis of lipids. Total cholesterol, LDL-C, and high-
density lipoprotein cholesterol (HDL-C) as well as triglycerides were
determined by enzymatic methods (CHOD-PAP and GPO-PAP;
Roche Diagnostics, Mannheim, Germany) on the day of blood collec-
tion in the laboratories of the Cologne University Medical Center
(inter-assay coefficient of variation for total cholesterol, LDL-C,
HDL-C, and triglycerides was 1.09, 2.79, 0.81, and 1.72%, respectively).
Serum was obtained by centrifugation at 1600 g for 30 min at 48C
within 15 min after venipuncture and aliquots were stored immediately
at 2808C for future analysis.
Non-denaturing polyacrylamide gradient gel electrophoresis (GGE)
of serum was performed in the laboratory of K.B. at the University
Hospital Zurich, Switzerland, in a blinded manner. Samples were
shipped from Germany in dry ice and immediately analysed by GGE
without re-freezing. Previous studies have shown that freezing and
thawing has no effect on the measurement of LDL subfractions.19 Gra-
dient gel electrophoresis was performed at 10–148C in 2–16% poly-
acrylamide gradient gels. Gels were subjected to electrophoresis for
24 h at 125 V in tris borate buffer (pH 8.3) as described previously.7,20
Gels were fixed and stained for lipids in a solution containing oil red O
in 60% ethanol at 558C. Gels were placed on a light source and photo-
graphed using a Luminescent Image Analyzer, LAS-3000 of Fujifilm.
Migration distance for each absorbance peak was determined and
the molecular diameter corresponding to each peak was calculated
from a calibration curve generated from the migration distance of
size standards of known diameter, which includes carboxylated latex
beads (Duke Scientific, Palo Alto, CA, USA), thyroglobulin, and apofer-
ritin (HMW Std, Pharmacia, Piscataway, NJ, USA) having molecular
diameters of 380, 170, and 122 A˚, respectively, and lipoprotein calibra-
tors of previously determined particle size. The coefficient of variation
in repeated measurements was 1.3%. Low-density lipoprotein subfrac-
tion distribution (LDL-I, -IIA, -IIB, -IIIA, -IIIB, -IVA, and -IVB) as percen-
tage of total LDL was calculated as described previously.7
Statistical analysis
Descriptive data are presented as mean values (SD) unless otherwise
stated. We performed multivariate analyses using generalized estimat-
ing equations to assess the influence of therapy on LDL subclass distri-
bution, controlling for within-subject patterns (clustering). We
adjusted for age, BMI, and baseline concentrations of LDL-C and trigly-
cerides. Statistical analyses were conducted using Stata version 9 (Sta-
taCorp, College Station, TX, USA). We used Stata’s xtgee command
to model panel data. All reported P-values were calculated two-sided.
Statistical significance was assumed at P-values ,0.05.
Results
Baseline subject characteristics are shown in Table 1 and were not
different among the three treatment groups. The flow of participants
K. Berneis et al.1634
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through the trial is shown in Figure 1. All subjects completed the
study and their adherence was excellent, as based on pill counts
[mean (SD) adherence, 99.1 (3.7)%]. As shown in Table 2, total
cholesterol and LDL-C levels significantly decreased in all treatment
groups (P, 0.001 for all), whereas triglycerides decreased only in
the groups receiving simvastatin. High-density lipoprotein-
cholesterol concentrations remained unchanged in all groups.
Significant changes in LDL subfraction distribution were
observed in all treatment groups after adjusting for age, BMI and
baseline concentrations of LDL-C and triglycerides (Wald x2
P , 0.05). The results are depicted in Figure 2. Adjusted compari-
sons within individual subclasses showed that ezetimibe treatment
significantly increased LDL-IIB (+11.2%), LDL-IIIA (+19.5%),
LDL-IIIB (+11.9%), LDL-IVA (+14.2%), and LDL-IVB (+16.7%)
(Table 2 and Figure 2A). Combination treatment (ezetimibe plus
simvastatin) significantly increased LDL-IIIB (+27%) and LDL-IVA
(+28.5%) (Table 2 and Figure 2B). Treatment with simvastatin
alone significantly increased LDL-IIB (+11.3%), LDL-IIIA
(+15.4%), LDL-IIIB (+17.3%), and LDL-IVA (+2.5%), but signifi-
cantly decreased LDL-IVB, the most atherogenic LDL subfraction
(216.7%, P ¼ 0.002) (Figure 2C). This effect was offset when eze-
timibe was added to simvastatin (Table 2, and Figures 2B and 3).
All treatments decreased the larger, more buoyant LDL-I
(Table 2 and Figures 2A–C ). The decrease was most pronounced
in the ezetimibe alone group (213.9%), followed by the combi-
nation group (27.3%) and smallest in the simvastatin alone
group (24.6%; Figure 3). The reported within-group changes did
not reach statistical significance in between-group comparisons
due to the overall small sample size.
In multivariate analyses there was a significant influence of base-
line LDL-C concentrations on changes in LDL subfraction distri-
bution in the ezetimibe alone group. The increase in atherogenic
sdLDL was more pronounced when baseline LDL-C was higher
and vice versa (data not shown).
None of the treatments had an effect on overall LDL particle
size (Table 2).
Discussion
One essential finding of our study is that treatment with ezetimibe
alone or in combination with a statin increases sdLDL proportions,
thus resulting in a more pro-atherogenic LDL subfraction profile.
Small dense LDL has been accepted as an emerging cardiovascular
risk factor by the National Cholesterol Education Program Adult
Treatment Panel III.21 Moreover, a consensus statement endorsed
by the American Diabetes Association and the American College
of Cardiology advocated measuring LDL particle concentration in
subjects at high risk for cardiometabolic disorders and pointed
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographic data and biochemical baseline characteristics of the study participants (total n 5 72)
Parameter Total cohort
(n5 72)
Ezetimibe only
(n5 24)
Ezetimibe plus
simvastatin (n5 24)
Simvastatin only
(n 5 24)
Age (years) 32 (9) 29 (7) 34 (11) 32 (9)
Height (cm) 181 (7) 181 (7) 181 (7) 182 (6)
Weight (kg) 85 (12) 82 (11) 84 (12) 87 (12)
BMI (kg/m2) 25.7 (3.2) 25.0 (3.3) 25.8 (3.1) 26.4 (3.2)
Fasting plasma glucose (mg/dL) 88 (8) 87 (6) 89 (2) 86 (7)
Smoking status
Current smoker [n (%)] 21 (29) 7 (29) 6 (25) 8 (33)
Ex-smoker [n (%)] 9 (12.5) 4 (17) 3 (13) 2 (8)
Never smoker [n (%)] 42 (58.3) 13 (54) 15 (63) 14 (58)
Serum lipoproteins
Total cholesterol (mg/dL) 189 (35) 180 (28) 194 (41) 194 (34)
LDL cholesterol (mg/dL) 111 (30) 105 (23) 116 (35) 113 (30)
HDL cholesterol (mg/dL) 64 (15) 64 (13) 61 (14) 65 (18)
Triglycerides (mg/dL) 95 (43) 78 (32) 106 (48) 101 (45)
LDL particle size (A˚) 276 (9) 279 (7) 273 (9) 277 (11)
LDL subclasses
LDL-I (%) 37.2 (6.7) 39.6 (5.5) 35.4 (7.3) 36.8 (6.7)
LDL-IIA (%) 17.4 (3.6) 16.3 (2.9) 19.1 (4.6) 16.8 (2.3)
LDL-IIB (%) 16.0 (4.3) 14.2 (1.8) 18.1 (5.3) 15.7 (4.1)
LDL-IIIA (%) 10.7 (2.6) 10.3 (1.6) 10.6 (2.4) 11.3 (3.5)
LDL-IIIB (%) 4.7 (1.0) 5.1 (1.0) 4.3 (1.0) 4.9 (0.9)
LDL-IVA (%) 6.8 (1.6) 7.2 (1.4) 6.2 (1.8) 7.0 (1.6)
LDL-IVB (%) 7.3 (2.1) 7.4 (1.7) 6.5 (2.2) 8.0 (2.2)
BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein. Data are presented as mean (SD) or counts (percentages). There were no significant
differences between the three treatment groups.
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out the pro-atherosclerotic effects of sdLDL.22 The mechanisms
through which sdLDL may promote atherosclerosis include
increased endothelial permeability, impaired clearance from the
circulation, easier oxidation and glycation, and increased ability
to bind to proteoglycans in the vessel wall.23,24
Although it cannot be fully excluded that the increased risk
associated with smaller LDL phenotype may also be a consequence
of the broader pathophysiology of which sdLDL are a part (e.g.
high triglycerides, low HDL-C, increased LDL particle number,
obesity, insulin resistance, diabetes, and metabolic syn-
drome),23,25– 27 some studies have shown that sdLDLs are a
strong and independent predictor of coronary artery disease
(CAD).28 Other studies have investigated whether the therapeutic
modification of LDL subfractions reduces cardiovascular risk. Such
investigations used angiographic changes as outcome variables and
have reported benefit in patients with a predominance of sdLDL
who received treatment such as statins and bile acid-binding
resins that tend to reduce the amount of such particles.8,29,30
In fact, various lipid-lowering drugs are able to favourably alter
sdLDL, and fibrates and nicotinic acid seem to be the most effec-
tive in this respect (reviewed in Gazi et al.31 and Rizzo et al.32). As
we were also able to show in the present study, simvastatin has
been found to have either no or only a marginal net effect on
LDL subfraction distribution.13 This is true for the majority of
the statins.33 Interestingly, rosuvastatin, the latest statin to be intro-
duced in the market, seems to be more efficient in modulating
plasma lipids and LDL subfractions (reviewed in Rizzo et al.13,34).
In contrast, the effects of the cholesterol absorption inhibitor eze-
timibe on LDL size and subfraction distribution have been contra-
dictory. Ezetimibe monotherapy was found to be associated with a
small but significant decrease in sdLDL concentrations and increase
in LDL particle size in patients with primary dyslipidaemia,35 mixed
hyperlipidaemia,36 and in obese and overweight patients with
hypercholesterolaemia.37 On the other hand, Ose et al.38 in a
12-week trial found no effects of ezetimibe monotherapy on
sdLDL concentrations and LDL particle size in patients with
hypercholesterolaemia. Moreover, in patients with mixed hyperli-
pidaemia Tribble et al.39 found that ezetimibe caused reductions
in both the large and sdLDL subfractions and had no effects on
LDL particle size. Furthermore, Geiss et al.40 found no effect of
ezetimibe on LDL subfraction distribution in patients concomi-
tantly treated with LDL apheresis and statins. Three recent
studies support our findings. Winkler et al.41 showed that in
patients with the metabolic syndrome, the combination of simvas-
tatin with ezetimibe reduces LDL radius of the sdLDL subfractions
even further. Moreover, Stojakovic et al.42 found that in patients at
high risk for coronary events, the addition of ezetimibe to fluvas-
tatin does not result in any further reduction of dense LDL
Figure 1 CONSORT flow diagram: flow of participants through the trial.
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Table 2 Plasma lipids, low-density lipoprotein size, and low-density lipoprotein subfraction distribution before and after treatment
Parameter Ezetimibe only Ezetimibe plus simvastatin Simvastatin only
Before
therapy
After
therapy
Mean per cent
change
P-valuea Before
therapy
After
therapy
Mean per cent
change
P-valuea Before
therapy
After
therapy
Mean per cent
change
P-valuea
Lipoprotein concentrations
Total cholesterol, mg/dL 180 (28) 159 (23) 211.2 (9.7) 0.0002 194 (41) 121 (25) 236.9 (8.1) ,0.0001 194 (34) 145 (24) 224.7 (7.9) ,0.0001
LDL cholesterol (mg/dL) 105 (23) 80 (16) 222.1 (10.2) ,0.0001 116 (35) 47 (19) 259.6 (9.7) ,0.0001 113 (30) 67 (22) 240.7 (11.5) ,0.0001
HDL cholesterol (mg/dL) 64 (13) 65 (16) +1.7 (11) 0.35 61 (14) 60 (14) 21.5 (8.5) 0.23 65 (18) 65 (16) +.7 (11.1) 0.88
Triglycerides (mg/dL) 78 (32) 88 (49) +27 (79) 0.57 106 (48) 90 (36) 28.9 (29.7) 0.0288 101 (45) 82 (39) 211.8 (39.9) 0.0386
LDL particle size (A˚) 279 (7) 279 (10) +.2 (3.3) 0.22 273 (9) 276 (8) +1.1 (2.6) 0.0975 277 (11) 276 (8) 2.4 (1.9) 0.22
LDL subclass composition
LDL-I (%) 39.6 (5.5) 33.9 (5.9) 213.9 (11.8) ,0.0001 35.4 (7.3) 31.8 (4.7) 27.3 (19.1) 0.0743 36.8 (6.7) 34.5 (5.7) 24.6 (16.7) ,0.0001
LDL-IIA (%) 16.3 (2.9) 16.1 (2.2) 2.5 (9.8) 0.89 19.1 (4.6) 18.7 (4.3) +.6 (20.1) 0.73 16.8 (2.3) 17.3 (2.0) +4.0 (10.1) 0.59
LDL-IIB (%) 14.2 (1.8) 15.8 (3.1) +11.2 (15.8) 0.0003 18.1 (5.3) 17.6 (3.2) +3.4 (27.2) 0.37 15.7 (4.1) 17.1 (3.1) +11.3 (16.3) 0.0002
LDL-IIIA (%) 10.3 (1.6) 12.1 (1.8) +19.5 (21.0) ,0.0001 10.6 (2.4) 11.5 (1.8) +13.6 (28.5) 0.0609 11.3 (3.5) 12.5 (2.6) +15.4 (24.3) ,0.0001
LDL-IIIB (%) 5.1 (1.0) 5.6 (1.0) +11.9 (19.2) 0.0021 4.3 (1.0) 5.2 (1.2) +27.0 (30.0) 0.0017 4.9 (.9) 5.6 (1.0) +17.3 (24.1) 0.0011
LDL-IVA (%) 7.2 (1.4) 8.2 (2.0) +14.2 (25.9) 0.0216 6.2 (1.8) 7.8 (2.2) +28.5 (32.1) 0.0002 7.0 (1.6) 6.9 (1.6) +2.5 (30.7) 0.0179
LDL-IVB (%) 7.4 (1.7) 8.3 (2.2) +16.7 (40.4) 0.0392 6.5 (2.2) 7.3 (2.9) +14.3 (30.8) 0.44 8.0 (2.2) 6.1 (1.8) 216.7 (37.4) 0.002
Data are presented as mean (SD). Each group comprised n ¼ 24 subjects.
aWald x2 test after adjusting for age, body mass index, baseline LDL cholesterol, and triglycerides.
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compared with fluvastatin alone. Tomassini et al.43 in a 6-week trial
compared the effects of ezetimibe/simvastatin with atorvastatin on
lipoprotein subfractions in patients with type 2 diabetes and
hypercholesterolaemia. Ezetimibe monotherapy was not evaluated.
They found that neither the combination of ezetimibe/simvastatin
nor atorvastatin alone significantly affected the LDL-IV cholesterol
subfraction. However, when subjects with triglyceride levels
,200 mg/dL were examined, a population similar to that of our
study, they also observed an increase, albeit not significant, of
the LDL-IV subfraction in the ezetimibe/simvastatin-treated
patients. To our knowledge, the present study is the first one to
examine whether ezetimibe modulates LDL size and subfraction
distribution in healthy individuals, a model which in a sense reflects
ezetimibe’s ‘true’ effects on a normal metabolic background.
In the present study, we investigated a group of healthy men to
assess the effects of ezetimibe, simvastatin, and their combination
on LDL particle size and subfraction distribution. We were able
to show that treatment with ezetimibe alone or in combination
with a statin did not alter LDL particle size but altered the LDL
subfraction distribution towards increased concentrations of
atherogenic small dense particles. Although simvastatin alone
also increased LDL-III subfractions, it significantly decreased the
smallest, most dense LDL fraction (LDL-IVB), which has been
found to be the best lipoprotein predictor of atherosclerotic
disease progression, even if it represents only a minor fraction of
total LDL.12 This potentially atheroprotective effect of simvastatin
was offset when ezetimibe was co-administered. These findings
may, at least partially, explain the lack of additional benefit of eze-
timibe added to simvastatin on atherosclerosis progression,
measured as changes in IMT, despite a significant additional
reduction in LDL-C levels, observed in the ENHANCE study.15
Although there is still no consensus on the clinical significance of
surrogate markers of cardiovascular risk, such as IMT,44 it should
be pointed out that data from a subsequent study with ezetimibe
were also disappointing; the Simvastatin and Ezetimibe in Aortic
Stenosis (SEAS) study showed that treatment with ezetimibe
(10 mg/day) plus simvastatin (40 mg/day) significantly reduced
LDL-C concentrations in patients with aortic stenosis, compared
with placebo, but did not affect the composite primary endpoint
of aortic-valve events and ischaemic events.45 Furthermore, the
recently published trial ARBITER6-HALTS casts some more
doubts on the clinical benefits of ezetimibe.46 In specific, the trial
showed that while extended-release niacin added to a statin
causes a smaller LDL-C reduction compared with ezetimibe
added to a statin, niacin had greater efficacy than ezetimibe regard-
ing beneficial changes in IMT. The findings of our trial may at least
Figure 2 Low-density lipoprotein subclass distribution (in %)
and changes from baseline. Low-density lipoprotein subclass dis-
tribution in the ezetimibe monotherapy group (A), combination
treatment group (ezetimibe plus simvastatin) (B), and simvastatin
monotherapy group (C ). Significant changes, as determined by
generalized estimating equations (Wald x2 P-values), adjusting
for age, body mass index, baseline low-density lipoprotein choles-
terol, and triglycerides, are indicated by asterisks [*P, 0.05,
(*)P, 0.1]. Data shown are mean values (SEM).
Figure 3 Per cent change from baseline in low-density lipopro-
tein subfractions in the three treatment groups. Data shown are
mean values (SEM).
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partially explain the lack of antiatherosclerotic effects of ezetimibe,
despite its stronger LDL-C lowering than the comparators.
Interestingly, we found that under treatment with ezetimibe
alone, a significant association existed between baseline LDL-C
concentrations and the pro-atherogenic changes of the LDL sub-
fractions. Considering that the population of the current study
was normocholesterolaemic and that ezetimibe is prescribed to
patients with much higher LDL-C levels, it can be postulated
that the pro-atherogenic effects of ezetimibe would be even
more pronounced in the latter population. Although it could be
argued that ezetimibe is usually prescribed along with a statin, a
group in which such an association was not observed, it should
be pointed out that ezetimibe monotherapy is a widely used
alternative for the treatment of hypercholesterolaemia in patients
with statin intolerance.47
Limitation of the study is the fact that the clinical relevance of
our findings remains to be established. Another limitation is the
fact that no a priori power calculations were made for changes
in LDL subfractions because the primary outcome parameter of
the study was change in LDL-C. Therefore, statistical between-
group changes did not reach significance due to the overall small
sample size. Strengths of the study include its randomized design
and robust statistical methodology, the blinded measurements of
LDL subclasses, and the use of a ‘drug-naı¨ve’ population, devoid
of co-medications and co-morbidities, which could potentially
alter lipid metabolism, and excellent treatment adherence. Treat-
ment duration was relatively short, which does not exclude that
the observed effects could be even more pronounced during long-
term treatment, especially considering the different plasma resi-
dence times of light LDL (1.7–2 days) and dense LDL (2.4–5
days).48,49
A 2-week treatment duration was chosen for this study since the
lipid-lowering effects of simvastatin reach maximum at day 14 and
remain stable thereafter.50 This was first shown in 2001 by the
group of Michael Davidson and was later confirmed for simvastatin
and other statins.50– 53 Regarding ezetimibe, Bays et al.54 first
showed that the maximum LDL-C-lowering effect is present
after 2 weeks of treatment, after which it remains stable. This
finding was confirmed also by others.
In conclusion, our findings suggest that treatment with ezetimibe
alone is associated with the development of a pro-atherogenic LDL
subfraction profile. Moreover, potentially atheroprotective effects
of simvastatin are offset by ezetimibe when co-administered. Car-
diovascular event outcome trials, which are underway, will hope-
fully provide additional insights into the effects of ezetimibe on
cardiovascular events.
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